Literature DB >> 9111500

Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood.

E Pizzichini1, M M Pizzichini, A Efthimiadis, J Dolovich, F E Hargreave.   

Abstract

BACKGROUND: Airway eosinophilic inflammation is a characteristic feature of asthma. This can be assessed directly by measurement of eosinophils and eosinophilic cationic protein (ECP) in sputum or indirectly by measurement of the same markers in blood. We investigated the performance of these markers of airway eosinophilic inflammation in a population of patients with asthma compared with control subjects and the extent to which the markers differed.
METHODS: In a cross-sectional study, subject characteristics were documented on day 1 and induced sputum and blood samples were obtained on day 2. Nineteen patients with asthma and 20 control subjects (10 healthy subjects and 10 smokers with nonobstructive bronchitis) were consecutively enrolled in the study. Sputum (selected from saliva) and blood samples were processed by persons blind to the clinical details. Results are presented as median values (minimum-maximum); differences were measured by Mann-Whitney U test. The accuracy of the tests (sensitivity and specificity) was measured by plotting the data in receiver-operating characteristic (ROC) curves and comparing the areas under the curve for each marker.
RESULTS: Patients with asthma in comparison with control subjects had a higher proportion of sputum eosinophils (5.2% [0.2% to 93%] vs 0.3% [0% to 1.7%], p < 0.001), higher numbers of blood eosinophils (350.0 x 10(6)/L [144.0 to 1520.0 x 10(6)/L] vs 155.0 x 10(6)/L [34.0 to 426.0 x 10(6)/L], p = 0.003), and higher levels of ECP in sputum (1040.0 micrograms/L [76.8 to 32,000.0 micrograms/L] vs 455.3 micrograms/L [54.4 to 1280.0 micrograms/L], p = 0.001) but not in serum (25.0 micrograms/L [5.6 to 52.4 micrograms/L] vs 16.5 micrograms/L [3.3 to 36.0 micrograms/L], p = 0.08). Markers of airway inflammation in induced sputum and blood samples were correlated with clinical and physiologic variables. The area under the ROC curve showed that eosinophils in sputum (0.90) are significantly more accurate markers than blood eosinophils (0.72) and serum ECP (0.67) (p = 0.02). Although the area under the ROC curve for sputum ECP was greater than those for blood eosinophils and serum ECP, the differences could have occurred by chance (p > or = 0.1).
CONCLUSION: We conclude that the proportion of eosinophils in sputum is a more accurate marker of asthmatic airway inflammation than the proportions of blood eosinophils or serum ECP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111500     DOI: 10.1016/s0091-6749(97)70082-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  28 in total

Review 1.  Association of sputum parameters with clinical and functional measurements in asthma.

Authors:  E Rosi; G Scano
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

2.  Occupational asthma in detail.

Authors:  Nick R Anthonisen
Journal:  Can Respir J       Date:  2010 Mar-Apr       Impact factor: 2.409

3.  Relationship among pulmonary function, bronchial hyperresponsiveness, and atopy in children with clinically stable asthma.

Authors:  Eugene Yang; Woojung Kim; Byoung Chul Kwon; Sung Yeon Choi; Myung Hyun Sohn; Kyu-Earn Kim
Journal:  Lung       Date:  2006 Mar-Apr       Impact factor: 2.584

4.  Periostin - A Novel Systemic Biomarker for Eosinophilic Airway Inflammation: A Case Control Study.

Authors:  Viswanathan Emprm; M G Rajanandh; A D Nageswari
Journal:  J Clin Diagn Res       Date:  2016-02-01

5.  Charcot-Leyden crystal protein/galectin-10 is a surrogate biomarker of eosinophilic airway inflammation in asthma.

Authors:  Sharmilee M Nyenhuis; Preeth Alumkal; Jian Du; Brian T Maybruck; Mark Vinicky; Steven J Ackerman
Journal:  Biomark Med       Date:  2019-06-03       Impact factor: 2.851

6.  Race is associated with differences in airway inflammation in patients with asthma.

Authors:  Sharmilee M Nyenhuis; Jerry A Krishnan; Alalia Berry; William J Calhoun; Vernon M Chinchilli; Linda Engle; Nicole Grossman; Fernando Holguin; Elliot Israel; Rick A Kittles; Monica Kraft; Stephen C Lazarus; Erik B Lehman; David T Mauger; James N Moy; Stephen P Peters; Wanda Phipatanakul; Lewis J Smith; Kaharu Sumino; Stanley J Szefler; Michael E Wechsler; Sally Wenzel; Steven R White; Steven J Ackerman
Journal:  J Allergy Clin Immunol       Date:  2017-01-06       Impact factor: 10.793

Review 7.  Montelukast: a review of its therapeutic potential in persistent asthma.

Authors:  B Jarvis; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

8.  Outcome of occupational asthma after removal from exposure: A follow-up study.

Authors:  Catherine Lemiere; Simone Chaboillez; Mélanie Welman; Karim Maghni
Journal:  Can Respir J       Date:  2010 Mar-Apr       Impact factor: 2.409

9.  Demonstration of bronchial eosinophil activity in seasonal allergic rhinitis by induced plasma exudation combined with induced sputum.

Authors:  L Greiff; M Andersson; C Svensson; M Linden; P Wollmer; C G Persson
Journal:  Thorax       Date:  1999-01       Impact factor: 9.139

10.  Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma.

Authors:  P G Gibson; J L Simpson; R Hankin; H Powell; R L Henry
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.